REFERENCES
- Meyer JM, Simpson GM (1997) From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatric Services 48: 1137–9.
- Fleishhacker WW (1995) New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 91 Suppl 388: 24– 30.
- Carpenter WJ, Buchanan RW (1994) Schizophrenia. N Eng J Med 330: 681–90.
- Goff DC, Baldessarini RJ (1993) Drug interactions with antipsychotic agents. J Clin Psychopharmacol 13: 57 -67.
- Hale AS (1995) Atypical antipsychotics and compliance in schizophrenia. Nord Psykiatr Tidsskr 49 (suppl. 35): 31–9.
- Kane JM (1999) Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 (suppl. 12): 13 -17.
- Meltzer HY (2000) Editorial overview. Antipsychotic drugs: a new era. Curr Opin CPNS Invest Drugs 2: 19–21.
- Kane JM, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–96.
- Tamminga CA (1997) The promise of new drugs for schizophrenia treatment. Can J Psychiatry 42: 265–73.
- Lieberman JA (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57 (suppl. 11): 68 -71.
- Brown RG, Pluck G (2000) Negative symptoms: the `pathology’ of motivation and goal-directed behaviour. Trends Neurosci 23: 412–17.
- Miyamoto S, Duncan GE, Mailman RB, Lieberman JA (2002) Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2: 25–39.
- Hale A, Azorin J-M, Kasper S, et al (2000) Sertindole improves both the positive and negative symptoms of schizophrenia: results of a Phase III trial. Int J Psych Clin Pract 4: 55 -62.
- Zimbroff DL, Kane JM, Tamminga CA, et al (1997) Controlled, dose -response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–91.
- H. Lundbeck A/S. Data on file.
- Kane JM (1998) Sertindole: a review of clinical efficacy. Int Clin Psychopharmacol 13 (suppl. 3): S59–64.
- Hale AS (1998) A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 13 (suppl. 3): S65–70.
- van Kammen DP, McEvoy JP, Targum SD, et al (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol (Berlin) 124: 168–75.
- Daniel DG, Wozniak P, Mack RJ, et al (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bul l 34: 61–9.
- Nabulsi AA, Braus AJ, Mack RJ, et al (1996) Reduction of hospital days in sertindole treated patients - one year findings. Poster presented at 149th Annual Meeting of the American Psychiatric Association (APA), New York, USA.
- Didriksen M (1995) Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 281: 241–50.
- Skarsfeldt T (1996) Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psycho-pharmacology 124: 126–33.
- Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388–98.